Vitamin D Levels Decline with Rising Number of Cardiometabolic Risk Factors in Healthy Adults: Association with Adipokines, Inflammation, Oxidative Stress and Advanced Glycation Markers

Zora Krivošiková, Martin Gajdoš, Katarína Šebeková

1 Department of Clinical and Experimental Pharmacotherapy, Medical Faculty, Slovak Medical University, Bratislava, Slovakia, 2 Institute of Molecular BioMedicine, Medical Faculty, Comenius University, Bratislava, Slovakia

kata.sebekova@gmail.com

Abstract

Introduction

Hypovitaminosis D associates with obesity, insulin resistance, hypertension, and dyslipoproteinemia. We asked whether the presence of multiple cardiometabolic risk factors, and which particular combination, exerts additive negative effects on 25(OH)D3 levels; and whether 25(OH)D3 levels associate with markers of inflammation and oxidative stress.

Subjects and Methods

In non-diabetic medication-free adults central obesity (waist-to-height ratio > 0.5); elevated blood pressure (systolic BP > 130 mm Hg and/or diastolic BP > 85 mm Hg); increased atherogenic risk (log(TAG/HDL) > 0.11); and insulin resistance (QUICKI < 0.322) were considered as cardiometabolic risk factors. 25(OH)D3 status was classified as deficiency (25(OH)D3 < 20 ng/ml); insufficiency (levels between 20-to-30 ng/ml), or as satisfactory (>30 ng/ml). Plasma adipokines, inflammatory and oxidative stress markers, advanced glycation end-products, and their soluble receptor were determined.

Results

162 subjects were cardiometabolic risk factors-free, 162 presented increased (i.e. 1 or 2), and 87 high number (i.e. 3 or 4) of cardiometabolic risk factors. Mean 25(OH)D3 decreased with rising number of manifested risk factors (36 ± 14 ng/ml, 33 ± 14 ng/ml, and 31 ± 15 ng/ml, respectively; PANOVA: 0.010), while prevalence of hypovitaminosis D did not differ significantly. Elevated blood pressure and insulin resistance appeared as significant determinants of hypovitaminosis D. Subjects presenting these risk factors concurrently displayed the lowest 25(OH)D3 levels (29 ± 15 ng/ml). Plasma adipokines, inflammatory and oxidative stress markers...
markers, advanced glycation end-products, and their soluble receptor generally differed significantly between the groups, but only advanced oxidation protein products and advanced glycation end-products associated fluorescence of plasma showed significant independent association with 25(OH)D3 levels.

Conclusion

In apparently healthy adults increasing number of cardiometabolic risk factors associates with poorer 25(OH)D3 status, while the association between 25(OH)D3 status and inflammatory or oxidative stress markers remains equivocal.

Introduction

Steroid hormone vitamin D is produced in dermis from 7-dehydrocholesterol through exposure to UV-B irradiation. Provitamin D3 quickly undergoes rearrangements to form stable vitamin D3, and enters circulation after binding to vitamin D binding protein (DBP). It is hydroxylated to 25(OH)D3 in the liver and thereafter to its active form 1,25(OH)2D3 by 1,α-hydroxylase in the kidneys. Moreover, a wide variety of extrarenal cells expressing vitamin D nuclear receptor—VDR (i.e. adipocytes, cells of the immune system, colon, pancreas, skin and the vasculature) synthesize 1,25(OH)2D3. This local production of vitamin D is responsible for extraskeletal modulation of various physiological processes: complex of vitamin D, VDR, and other transcription factors (such as retinoid X receptor); and binds to vitamin D response elements of as many as 2000 genes to regulate their expression directly or in directly [1]. Hence hypovitaminosis D extends its negative effects beyond calcium homeostasis and skeletal health playing a pathophysiological role in different noncommunicable diseases.

Vitamin D deficiency may contribute to manifestation of different cardiometabolic risk factors via distinct biological pathways. Vitamin D may modulate blood pressure (BP) by suppression of the renin–angiotensin–aldosterone system, direct effects on vascular cells, renoprotective effects, and those on calcium metabolism, including prevention of secondary hyperparathyroidism [2–4]. Link between vitamin D and glucose homeostasis is complex. Pancreatic β-cells express vitamin D receptors and 1,α-hydroxylase enzymes, and vitamin D response element is present in insulin gene promoter region [5, 6]. Thus, vitamin D affects insulin synthesis, release, β-cell function, as well as insulin sensitivity [7–9]. Moreover, polymorphisms in vitamin DBP, VDR, and 1,α-hydroxylase genes might link vitamin D deficiency to insulin resistance (reviewed in [10]). Mitochondria possess both a functional renin-angiotensin system and vitamin D receptors, and their dysfunction has been implicated in the pathogenesis of hypertension and insulin resistance via enhanced generation of reactive oxygen species, induction of endoplasmic-reticulum stress, and inflammation [11]. Also adipocytes express vitamin D receptors and 1,α-hydroxylase enzymes. Vitamin D may affect body fat mass by inhibiting lipid accumulation and key adipogenic transcription factors during adipocyte differentiation [12]. It may modulate lipid profile indirectly through its effect on serum parathormone and/or on the calcium balance, or via modulation of insulin secretion and sensitivity [13–16].

Several clinical studies indicate an association between inadequate vitamin D status and single cardiometabolic risk factors such as obesity (central obesity in particular), hyperglycemia, insulin resistance, hypertension, dyslipoproteinemia, and disbalance of immune function (reviewed in [1, 17–19]). In general population, obese subjects, patients with hypertension or
impaired fasting glucose, low 25(OH)D₃ levels associate with higher levels of systemic inflammation, glycoxidative, lipoxidative, and carbonyl stress markers [20, 21]. Vitamin D influences production of adipokines and the inflammatory response in adipose tissue [12]. It regulates genes encoding pro-inflammatory cytokines, downregulates Toll-like receptors expression [8, 9], and counteracts the inflammatory effects induced by cytokines [22, 23]. Thus, hypovitaminosis D (serum 25(OH)D₃ levels <30 ng/ml are classified as insufficiency; those <20 ng/ml as deficiency) represents a global problem [24].

Owing to distinct pathomechanisms linking different cardiometabolic risk factors to vitamin D status, we hypothesized that presence of multiple cardiometabolic risk factors should be associated with lower 25(OH)D₃ levels and a higher prevalence of hypovitaminosis D. We also asked which particular combination of cardiometabolic risk factors associates with poor 25(OH)D₃ status. To this point, non-diabetic apparently healthy adults presenting increased (1 or 2) and high number (3 or 4) of cardiometabolic risk factors were compared with their cardiometabolic risk factors-free counterparts. We also studied the association of vitamin D₃ status with non-standard cardiometabolic risk factors, such as adipokines, markers of microinflammation and oxidative stress, advanced glycation end products (AGEs), and their soluble receptor (sRAGE).

Subjects and methods

This cross-sectional study was conducted in accordance to the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the Slovak Medical University in Bratislava. All subjects signed an informed consent to participate.

Study population

Apparently healthy volunteers residing in Bratislava and surroundings, declaring that they do not suffer from and are not treated for any acute or chronic illness, and did not take any vitamin D supplements during last 6 months, were recruited. Elevated fasting plasma glucose (FPG ≥ 7 mmol/l), decreased renal function (eGFR ≤ 0.6 ml/s/1.73m²), pregnancy and lactation were exclusion criteria.

From among 452 recruited subjects aged 18-to-81 years who underwent blood sampling during winter period 41 were excluded: 11 in whom 25(OH)D₃ levels were not determined for technical reasons, 17 presenting FPG ≥ 7 mmol/l, 2 with eGFR ≤ 0.6 ml/s/1.73m², and 11 with incomplete data for unequivocal classification of cardiometabolic risk factors. Thus, data from 411 subjects was available for analysis.

Procedures

Body weight, height, waist circumference, and BP were measured in the outpatients department in the morning hours. Blood pressure was measured at forearm in sitting position after 10 min. rest and the mean of last 2 measurements out of 3 taken was recorded. Self-reported smoking status was recorded (current smoker/non-smoker). Blood was taken from antecubital vein after overnight fasting.

Research variables

Standard blood chemistry (glucose, lipid profile, creatinine, uric acid, albumin) was analyzed immediately (Vitros 250 analyzer, Johnson&Johnson, Rochester, NY, USA). Aliquoted plasma samples were stored at -80°C for special analyses. Commercial ELISA sets according to manufacturers’ instructions were used to determine high sensitive C-reactive protein (hsCRP,
Immundiagnostik AG, Bensheim, Germany), interleukine-6 (Human IL-6, R&D Systems, Minneapolis, MN, USA), high sensitive transforming growth factor-α (Human TNF-α/TNFSF1A, R&D Systems, Minneapolis, MN, USA), adiponectin (Human Adiponectin, R&D Systems, Minneapolis, MN, USA), leptin (Human Leptin, R&D Systems, Minneapolis, MN, USA), resistin (Human Resistin, R&D Systems, Minneapolis, MN, USA), Nε-carboxymethyllysine (CML, Microcoat, Bernried, Germany) and soluble receptor for advanced glycation end products (sRAGE, R&D Systems, Minneapolis, MN, USA). Serum concentrations of 25-hydroxyvitamin D was analyzed by RIA method (25(OH)D3, Immuno Diagnostic system, Boldon, UK) and intact parathyroid hormone by IRMA method (PTH, Immunotech, Marseille, France). Advanced oxidation protein products (AOPPs) were determined after precipitation of plasma lipids [25, 26], and advanced glycation end products-associated fluorescence of plasma (AGE-Fl) according to Munch et al. [27].

Body mass index (BMI), waist-to-height ratio (index of central obesity, ICO), mean arterial pressure (MAP), pulse pressure (PP), quantitative insulin sensitivity check index (QUICKI) [28], atherogenic index of plasma (AIP, log(TAG/HDL)) [29], and glomerular filtration rate (eGFR) [30] were calculated. CML, AGE-Fl and AOPPs were corrected for plasma albumin.

Classification of cardiometabolic risk factors

Presence of cardiometabolic risk factors was classified as follows: central obesity: ICO > 0.5 [31]; elevated BP: systolic BP (SBP) ≥ 130 mm Hg and/or diastolic BP (DBP) ≥ 85 mm Hg; increased atherogenic risk: AIP ≥ 0.11 [29]; insulin resistance: QUICKI < 0.322. Subjects were classified into 3 groups: those not presenting cardiometabolic risk factors; subjects presenting increased (i.e. 1 or 2); and those presenting high number (i.e. 3 or 4) of risk factors.

Vitamin D status classification

Vitamin D status was classified as deficiency if plasma vitamin D concentrations ≤ 20 ng/ml, as insufficiency if levels ranged between 20-to-30 ng/ml, while higher levels were considered as satisfactory.

Statistical analysis

Normality of data distribution and equality of variances were tested (Kolmogorov-Smirnov and Levene’s test, respectively). Skewed data were logarithmically (ln) transformed for statistical evaluation, but for better understanding data are given as mean ± standard deviation (± SD); if not given differently. Two groups were compared using Student’s t-test, comparison between 3 groups was performed using one way analysis of variance (ANOVA) with post-hoc Scheffe’s test. Categorical data were compared by chi-square test. General linear model (GLM) was employed to study the impact of cardiometabolic risk factors on 25(OH)D3 status. Binary logistic regression analysis was used to provided evidence on whether the cardiometabolic risk factors, gender and renal function could be considered independent variables for prediction of satisfactory 25(OH)D3 status. In Model 1 number of cardiometabolic risk factors, gender, and ln eGFR were used as predictors; in Model 2 number of risk factors was replaced by categories (absence/presence) of elevated blood pressure, insulin resistance, central obesity and atherogenic index. Classification tree was employed to study the impact of independent variables on 25(OH)D3 levels. P < 0.05 (2-sided) was considered significant. Statistical analyses were performed using program SPSS version 22 (SPSS Inc., Chicago, IL, USA).
Results

Cohort characteristics

Study participants were 36 ± 14 years of age, on average slightly overweight (average BMI: 25 ± 5 kg/m²) and not presenting central obesity (ICO: 0.50 ± 0.08), (Table 1). Except for mildly decreased mean eGFR they presented mean BP values, variables characterizing glucose homeostasis and lipid metabolism, concentrations of uric acid, albumin, and inflammatory markers (hsCRP, IL-6) within the reference range (Tables 1 and 2).

25(OH)D₃ status

25(OH)D₃ levels ranged between 5.8–96.3 ng/ml (mean: 33.4 ± 14.5 ng/ml; Fig 1). 17.5% of subjects were 25(OH)D₃ deficient, 28.7% presented 25(OH)D₃ insufficiency, and satisfactory 25(OH)D₃ levels were revealed in 53.8% of participants (Table 1).

25(OH)D₃ levels and cardiometabolic risk factors

Cardiometabolic risk factors-free subjects presented significantly higher 25(OH)D₃ levels (35.5 ± 14.2 ng/ml) in comparison with groups presenting increased (32.6 ± 14.3 ng/ml) and high (31.0 ± 15.1 ng/ml) number of cardiometabolic risk factors (Fig 1). However, the frequencies of 25(OH)D₃ deficiency, insufficiency, and satisfactory levels did not differ significantly among the groups (Table 3). Mean 25(OH)D₃ levels were similar among the groups presenting 25(OH)D₃ deficiency, insufficiency, and satisfactory levels regardless of the presence or absence of cardiometabolic risk factors (Table 3). Gender or smoking status showed no significant impact on 25(OH)D₃ concentrations either in the whole cohort, or in subgroups with regard to 25(OH)D₃ status, and presence of cardiometabolic risk factors.

Thirty-eight % of subjects presented elevated BP values, 43% were centrally obese, 19% were insulin resistant, and 26% presented elevated atherogenicity of plasma. Those presenting elevated BP had significantly lower 25(OH)D₃ levels in comparison with their normotensive counterparts (31.4 ± 14.5 ng/ml vs. 34.6 ± 14.4 ng/ml, p = 0.026). Presence of insulin resistance (31.2 ± 15.3 ng/ml vs. 33.9 ± 14.3 ng/ml, p = 0.053), central obesity (32.3 ± 14.7 ng/ml vs. 34.3 ± 14.3 ng/ml, p = 0.11), and increased atherogenic index of plasma (32.3 ± 14.7 ng/ml vs. 33.8 ± 14.4 ng/ml, p = 0.24) was reflected only with trends towards lower levels. In comparison with cardiometabolic risk factors-free subjects presenting mean 25(OH)D₃ of 35.5 ± 14.2 ng/ml those suffering solely from insulin resistance displayed significantly lower concentrations (n = 12; 27.3 ± 13.1 ng/ml; p = 0.022), while in absence of other risk factors subjects presenting elevated BP (n = 40; 31.8 ± 15.6 ng/ml; p = 0.08); or central obesity (n = 31; 32.8 ± 14.0 ng/ml; p = 0.26), or increased atherogenic risk (n = 14; 30.4 ± 11.9 ng/ml; p = 0.13) showed only tendency towards lower 25(OH)D₃ concentrations.

In Model 1 binary logistic regression indicated that in comparison with cardiometabolic risk factors-free subjects those presenting 1-to-2 cardiometabolic risk factors are 2.3-fold less likely to present satisfactory 25(OH)D₃ status (B: -0.84, p = 0.015), and those presenting 3-to-4 risk factors are 4.3-fold less likely (B: -1.45, p = 0.001). Male gender (B: 0.48, p = 0.13) and ln eGFR (B: -1.35, p = 0.8) were not significant independent predictors. The model was significant (Omnibus test: 0.008), predicted correct classification in 76%, and the dependent variables accounted for 5-to-7% of the variance (Cox & Snell and Nagelkarte square). Model 2 showed that elevated blood pressure and insulin resistance decrease the probability of being 25(OH)D₃ sufficient (2.9-fold, p = 0.003 and 2.4-fold, p = 0.044, respectively); while the impact of gender, presence of central obesity, increased AIP and ln eGFR was insignificant (Omnibus test: 0.003,
Table 1. Cohort characteristics: anthropometric data, blood pressure, standard blood chemistry variables and 25(OH)D3 levels.

|                      | All       | 0          | 1–2        | 3–4        | p (ANOVA) |
|----------------------|-----------|------------|------------|------------|-----------|
| N                    | 411       | 162        | 162        | 87         |           |
| Gender (F/M) (n,%)   | 240/171(58%/42%) | 129/33(80%/20%) | 87/75(54%/46%) | 24/63(28%/72%) | 0.001\
| Age (years)          | 35.9 ± 14.1 | 30.0 ± 8.9 | 36.2 ± 13.9*** | 46.1 ± 14.6***+++ | <0.001\
| Weight (kg)          | 74.4 ± 17.1 | 62.9 ± 9.7 | 76.8 ± 15.4*** | 91.5 ± 15.1***+++ | <0.001\
| Waist (cm)           | 86.2 ± 14.6 | 75.0 ± 6.7 | 87.9 ± 11.3*** | 104.1 ± 11.0***+++ | <0.001\
| Height (cm)          | 172.0 ± 9.7 | 170.1 ± 8.5 | 172.6 ± 10.9 | 174.1 ± 8.7** | 0.004\
| BMI (kg/m²)          | 25.1 ± 4.8 | 21.6 ± 2.1 | 25.7 ± 4.1*** | 30.2 ± 4.3***+++ | <0.001\
| ICO                  | 0.50 ± 0.08 | 0.44 ± 0.03 | 0.51 ± 0.07*** | 0.60 ± 0.07***+++ | <0.001\
| SBP (mm Hg)          | 124.4 ± 14.4 | 114.4 ± 7.5 | 127.2 ± 13.3*** | 137.6 ± 13.1***+++ | <0.001\
| DBP (mm Hg)          | 76.7 ± 8.5 | 72.0 ± 6.5 | 78.0 ± 7.8*** | 83.4 ± 7.6***+++ | <0.001\
| MAP (mm Hg)          | 92.6 ± 9.5 | 86.1 ± 5.7 | 94.4 ± 8.4*** | 101.5 ± 8.1***+++ | <0.001\
| PP (mm Hg)           | 47.7 ± 11.1 | 42.5 ± 7.9 | 48.3 ± 11.3*** | 49.3 ± 11.3***+++ | <0.001\
| FPG (mmol/l)         | 5.2 ± 0.6 | 4.9 ± 0.4 | 5.1 ± 0.6*** | 5.7 ± 0.7***+++ | <0.001\
| Fls (µl/ml)          | 10.0 ± 8.3 | 6.9 ± 2.6 | 9.6 ± 7.8** | 16.5 ± 11.6***+++ | <0.001\
| QUICKI               | 0.351 ± 0.035 | 0.365 ± 0.025 | 0.354 ± 0.037** | 0.320 ± 0.029***+++ | <0.001\
| Chol (mmol/l)        | 4.7 ± 0.9 | 4.4 ± 0.8 | 4.6 ± 0.9** | 5.3 ± 0.9***+++ | <0.001\
| HDL-C (mmol/l)       | 1.4 ± 0.4 | 1.5 ± 0.4 | 1.4 ± 0.4*** | 1.1 ± 0.2***+++ | <0.001\
| LDL-C (mmol/l)       | 3.7 ± 0.8 | 2.4 ± 0.7 | 2.7 ± 0.8** | 3.2 ± 0.7***+++ | <0.001\
| VLDL-C (mmol/l)      | 0.5 ± 0.3 | 0.4 ± 0.2 | 0.5 ± 0.3*** | 0.9 ± 0.3***+++ | <0.001\
| TAG (mmol/l)         | 1.3 ± 0.9 | 0.8 ± 0.3 | 1.2 ± 0.7*** | 2.2 ± 1.1***+++ | <0.001\
| AIP                  | -0.10 ± 0.33 | -0.30 ± 0.21 | -0.10 ± 0.30*** | 0.28 ± 0.24***+++ | <0.001\
| Albumin (g/l)        | 47.8 ± 5.3 | 47.6 ± 5.3 | 48.2 ± 5.2 | 46.8 ± 5.6 | 0.26\
| Creatinine (µmol/l)  | 85.8 ± 16.0 | 80.7 ± 13.0 | 87.7 ± 17.3*** | 92.0 ± 15.9*** | 0.0030\
| eGFR (ml/s/1.73m²)   | 1.29 ± 0.24 | 1.34 ± 0.21 | 1.28 ± 0.23* | 1.23 ± 0.25*** | 0.001\
| Uric acid (mmol/l)   | 281 ± 75 | 251 ± 63 | 289 ± 73*** | 354 ± 63***+++ | <0.001\
| Vitamin D₃ (ng/ml)   | 33.4 ± 14.5 | 35.5 ± 14.2 | 32.6 ±14.3* | 31.0 ± 15.1* | 0.010\
| PTH (pg/ml)          | 43.1 ± 24.2 | 35.5 ± 19.5 | 45.1 ± 23.3*** | 53.5± 28.9***+++ | <0.001\
| Smoking (yes/no)     | 101/30 (25%/75%) | 40/122 (25%/75%) | 43/119 (27%/73%) | 18/69 (21%/79%) | 0.59{$\text{**}$}\n
Central obesity: waist-to-height ration >0.5 [31]; elevated BP: systolic BP (SBP) >130 mm Hg and/or diastolic BP (DBP) >85 mm Hg; increased atherogenic risk: AIP ≥ 0.11 [29]; and insulin resistance: QUICKI < 0.22 were considered as factors indicated increased cardiometabolic risk. 0: no risk factor presented (n = 162); 1–2: subjects with 1 or 2 risk factors (n = 162); 3–4: subjects presenting 3 or 4 risk factors (n = 87); F: females; M: males; BMI: body mass index; ICO: index of central obesity; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; PP: pulse pressure; FPG: fasting plasma glucose; Fls: fasting plasma insulin; QUICKI: quantitative insulin sensitivity check index; CHOL: total cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; VLDL-C: very low density lipoprotein cholesterol; TAG: triacylglycerols; AIP: atherogenic index of plasma; eGFR: estimated glomerular filtration rate; Vitamin D₃: plasma 25(OH)D₃; PTH: intact parathormone; chi: chi-square
*: p<0.05 vs. cardiometabolic risk factors free subjects
**: p<0.01 vs. cardiometabolic risk factors free subjects
***: p<0.001 vs. cardiometabolic risk factors free subjects
+: p<0.05 vs. subjects presenting 1 or 2 cardiometabolic risk factors
++: p<0.01 vs. subjects presenting 1 or 2 cardiometabolic risk factors
++++: p<0.001 vs. subjects presenting 1 or 2 cardiometabolic risk factors; {italics}: statistical evaluation performed on logarithmically transformed data

predicted correct classification: 76%, Cox & Snell and Nagelkarte square: 8% and 12%, respectively).

doi:10.1371/journal.pone.0131753.t001
Table 2. Cohort characteristics: inflammatory and oxidative stress markers, adipokines and advanced glycation end products.

| Marker                        | All     | 0       | 1–2     | 3–4     | p (ANOVA) |
|-------------------------------|---------|---------|---------|---------|-----------|
|                               | 411     | 162     | 162     | 87      |           |
| hsCRP (mg/l)                  | 2.3 ± 3.2| 1.7 ± 2.9| 2.5 ± 3.3**| 3.3 ± 3.3***+++| <0.001    |
| IL-6 (pg/ml)                  | 2.9 ± 2.7| 2.9 ± 3.0| 3.0 ± 2.7| 2.5 ± 1.9| 0.36      |
| hsTNF-α (pg/ml)               | 2.5 ± 3.3| 2.2 ± 2.0| 2.8 ± 3.5| 2.5 ± 4.5| 0.09      |
| Adiponectin (µg/ml)           | 8.2 ± 4.8| 9.6 ± 4.6| 8.1 ± 4.9***| 5.6 ± 3.8**+++| <0.001    |
| Leptin (ng/ml)                | 15.9 ± 21.4| 13.3 ± 10.5| 14.7 ± 14.1| 22.9 ± 39.2 **+++| <0.001    |
| Resistin (ng/ml)              | 10.7 ± 4.0| 10.1 ± 3.5| 10.6 ± 4.1| 12.1 ± 4.4***| <0.001    |
| CML/Alb (µg/g)                | 26.2 ± 6.7| 27.4 ± 6.7| 25.6 ± 6.3| 24.0 ± 7.1*| 0.014     |
| AGE-F1/Alb (AU/g)             | 6.3 ± 2.0| 6.3 ± 2.2| 6.0 ± 1.8| 7.0 ± 2.2**| 0.007     |
| AOPP/Alb (µmol/g)             | 1.6 ± 0.9| 1.5 ± 0.9| 1.7 ± 0.9| 1.6 ± 0.8| 0.06      |
| sRAGE (pg/ml)                 | 1263 ± 440| 1320 ± 456| 1265 ± 428| 1073 ± 374***| 0.001     |

Central obesity: waist-to-height ratio >0.5 [31]; elevated BP: systolic BP (SBP) ≥ 130 mm Hg and/or diastolic BP (DBP) ≥ 85 mm Hg; increased atherogenic risk: AIP ≥ 0.11 [29]; and insulin resistance: QUICKI < 0.322 were considered as factors indicated increased cardiometabolic risk. 0: no risk factor presented (n = 162); 1–2: subjects with 1 or 2 risk factors (n = 162); 3–4: subjects presenting 3 or 4 risk factors (n = 87); hsCRP: high sensitive C-reactive protein; IL-6: interleukine-6; hsTNF-α: high sensitive tumor necrosis factor-α; CML: N-(carboxymethyl)lysine; Alb: albumin; AGE-F1: advanced glycation end products associated fluorescence of plasma; AU: arbitrary units; AOPP: advanced oxidation protein products; sRAGE: soluble receptor for advanced glycation end products.

*: p<0.05 vs. cardiometabolic risk factors free subjects
**: p<0.01 vs. cardiometabolic risk factors free subjects
***: p<0.001 vs. cardiometabolic risk factors free subjects
+: p<0.05 vs. subjects presenting 1 or 2 cardiometabolic risk factors
++: p<0.01 vs. subjects presenting 1 or 2 cardiometabolic risk factors
+++: p<0.001 vs. subjects presenting 1 or 2 cardiometabolic risk factors; *italics*: statistical evaluation performed on logarithmically transformed data.

The impact of particular combination of CM risk factors on 25(OH)D3 levels was further investigated using SPSS AnswerTree, with age forced in as an influence variable (Fig 2).

AnswerTree selected BP as a main determinant: Subjects presenting elevated BP displayed lower 25(OH)D3 levels in comparison with their normotensive counterparts. Insulin resistant subjects with elevated BP displayed the lowest 25(OH)D3 levels. All of them were also centrally obese (ICO: 0.62 ± 0.06), and all 27 subjects presenting 4 risk factors were assigned into this group. Among insulin sensitive subjects with elevated BP males presented lower 25(OH)D3 levels than females. Normotensives without increased atherogenic risk displayed slightly lower 25(OH)D3 levels if compared with their counterparts with increased atherogenic risk. However, in the former group insulin resistance was associated with the second lowest 25(OH)D3 levels. Forty percent of these subjects were centrally obese.

Cardiometabolic risk factors and oxidative and inflammatory markers, adipokines

Due to shortage of plasma uric acid, sRAGE, CML, AOPPs and AGE-associated fluorescence could not be quantified in 54 subjects. With regard to the presence of cardiometabolic risk factors the groups differed significantly by all variables except for albuminemia, IL-6, hsTNF-α, and AOPP/Alb levels (Table 2). If compared with cardiometabolic risk factors-free subjects those presenting 1 or 2 risk factors displayed significantly lower eGFR and adiponectin levels, higher uric acid and hsCRP concentrations, but similar levels of leptin, resistin, CML/Alb,
AGE-Fl/Alb and sRAGE. Subjects bearing 3 and 4 risk factors displayed significantly lower eGFR, adiponectin, CML/Alb and sRAGE levels; and higher uric acid, hsCRP, leptin, resistin, and AGE-Fl/Alb levels in comparison with the risk factors-free subjects. Uric acid, hsCRP, leptin, resistin, and AGE-Fl/Alb levels were significantly higher and those of adiponectin, CML/Alb and sRAGE lower in subjects presenting high number of risk factors in comparison with their counterparts presenting 1 and 2 risk factors.

Table 3. 25(OH)D₃ status and plasma levels according to presence of cardiometabolic risk factors.

|                      | 0 (0 risk factors) | 1–2 (1–2 risk factors) | 3–4 (3–4 risk factors) | p       |
|----------------------|--------------------|------------------------|------------------------|---------|
| **Frequencies (n; %)** |                    |                        |                        |         |
| Deficiency           | 72 (17.5%)         | 19 (11.7%)             | 31 (19.1%)             | 22 (25.3%) |
| Insufficiency        | 118 (28.7%)        | 46 (28.4%)             | 45 (27.8%)             | 27 (31.0%) |
| Satisfactory         | 221 (53.8%)        | 97 (59.1%)             | 86 (53.1%)             | 38 (43.7%) |
| **Levels (ng/ml)**   |                    |                        |                        |         |
| Deficiency           | 15.5 ± 3.4         | 15.0 ± 3.3             | 15.4 ±3.3              | 16.0 ± 3.7 |
| Insufficiency        | 26.3 ± 8.7         | 27.7 ± 10.7            | 24.6 ±2.7              | 27.0 ± 11.1 |
| Satisfactory         | 43.1 ± 11.0        | 43.3 ± 10.3            | 43.0 ±11.3             | 42.5 ± 12.6 |

Central obesity: waist-to-height ratio >0.5 [31]; elevated blood pressure (BP): systolic BP >130 mm Hg and/or diastolic BP >85 mm Hg; increased atherogenic risk: AIP ≥0.11 [29]; and insulin resistance: QUICKI<0.322 were considered as factors indicated increased cardiometabolic risk. 0: no risk factor presented (n = 162); 1–2: subjects with 1 or 2 risk factors (n = 162); 3–4: subjects presenting 3 or 4 risk factors (n = 87). chi: chi-square; otherwise ANOVA p indicated; italics: statistical evaluation performed on logarithmically transformed data.

doi:10.1371/journal.pone.0131753.t003
Impact of 25(OH)D3 on oxidative and inflammatory markers, and adipokines

GLM with ln 25(OH)D3, ln eGFR, and cardiometabolic risk factors as covariates (or gender as a fixed factor if appropriate) did not reveal significant independent impact of 25(OH)D3 either on oxidative and inflammatory markers, or adipokines. Neither binary logistic model nor SPSS AnswerTree assigned either non-standard marker as independent determinant of 25(OH)D3 status.

Discussion

To the best of our knowledge this is a first study examining the 25(OH)D3 status in relation to potential additive effect of manifested number of standard cardiometabolic risk factors in non-
diabetic medication-free adults. Our data suggests, that in non-diabetic medication-free adults increasing number of cardiometabolic risk factors is associated with lower 25(OH)D$_3$ levels. Elevated blood pressure combined with insulin resistance were associated with the lowest 25(OH)D$_3$ levels; and low levels were also linked with insulin resistance in normotensive subjects not presenting increased atherogenic risk. It remains unclear whether hypovitaminosis D in apparently healthy medication free subjects manifests preferentially by increased BP and insulin resistance, or whether subjects presenting particular clustering of cardiometabolic risk factors are more prone to develop hypovitaminosis D. In the presence of cardiometabolic risk factors the levels of adipokines, biomarkers of inflammation, and oxidative stress were significantly altered. However, we did not reveal a significant impact of interaction between 25(OH)D$_3$ levels and cardiometabolic risk factors on circulating non-standard biomarkers. This might imply that in apparently healthy non-diabetic adults different pathomechanisms than 25(OH)D$_3$ deficiency per se play crucial role in the induction of microinflammation and oxidative stress, regulation of AGEs/RAGE axis, or modulation of adipokines.

25(OH)D$_3$ status

In comparison to other Central European studies on general population in latitudes similar to that of Bratislava, our cohort presented mean 25(OH)D$_3$ levels (33.4 ± 14.5 ng/ml) within the upper reported range and a rather high (almost 54%) prevalence of satisfactory 25(OH)D$_3$ levels (>30 ng/ml) [32–34]. However, this finding might not accurately reflect 25(OH)D$_3$ status in general population of Slovak adults, since participation in the study was on voluntary basis and it cannot be excluded that we investigated an “over-healthy” population. Data on vitamin D status in general Slovak population are not available. Small studies in different patients’ groups report 64%-to-100% prevalence of levels <30 ng/ml [35–38].

25(OH)D$_3$ and standard cardiometabolic risk factors

Blood pressure and insulin resistance. In humans vitamin D deficiency associates with increased BP and the risk of developing hypertension (reviewed in [39, 40]). As expected, our subjects presenting cardiometabolic risk factors had elevated BP values (including MAP and PP) and showed lower 25(OH)D$_3$ levels than their risk factors-free counterparts. Elevated BP appeared consistently as the most prominent cardiometabolic risk factor associated with low 25(OH)D$_3$ levels. It remains unclear whether this observation reflects the high susceptibility of BP-regulating mechanisms to hypovitaminosis D per se or whether modulating factors (e.g. genetic, environmental, life-style, etc.) not followed in present study interplay.

Observational studies in humans reported positive association between vitamin D status and insulin secretion and insulin sensitivity (reviewed in [10, 41]). Recent meta-analyses of prospective studies in apparently healthy adults showed that having vitamin D levels in upper vs. lower tertile at baseline is associated with a 16% lower future risk of developing insulin resistance [42]. In our study, insulin resistant normotensive subjects not presenting increased atherogenic lipid profile displayed low 25(OH)D$_3$ levels and the lowest mean 25(OH)D$_3$ levels were revealed in insulin resistant subjects presenting elevated BP. The latter data match those of Abassi et al. showing that the most insulin resistant quartile of patients with essential hypertension presented the lowest 25(OH)D$_3$ levels [43]. Interestingly, all our subjects assigned to the group with the lowest 25(OH)D$_3$ levels were also centrally obese and 64% of them presented increased atherogenic risk. Whether particularly combination of elevated blood pressure and insulin resistance generally associates with lower 25(OH)D$_3$ levels remains to be confirmed in further studies. If affirmed, it might be speculated that particularly hypertensive insulin resistant subjects would benefit from vitamin D repletion most.
Atherogenic dyslipidemia. Low 25(OH)D₃ levels are associated with an unfavorable lipid profile [40, 44–47]. We confirmed the data from Canadian study, which showed that rising number of cardiometabolic risk factors is associated with worsening of lipid profile components as well as poorer vitamin D status [48]. However, our results do not support 25(OH)D₃ status as a decisive factor in an induction of unfavorable lipid profile in apparently healthy general population; our normotensive subjects with increased atherogenic risk presented similar 25(OH)D₃ levels if compared with their counterparts with low atherogenic risk. Atherogenic profile neither exhibited significant impact on 25(OH)D₃ status in the binary logistic regression analysis, nor in the hypertensive branch of the decision tree. Thus, further studies in different populations are definitely needed to elucidate the association between vitamin D status and atherogenic risk with regard to the manifestation of other cardiometabolic risk factors.

Central obesity. Obese humans present generally low vitamin D status (reviewed in [49]). It remains unclear whether local conversion or trapping from circulation represent main source of 25(OH)D₃ deposited in human adipose tissue [50]. Weight reduction is not associated with significant change in circulating 25(OH)D₃ levels or its content in adipose tissue [50]. In our cohort central obesity did not appear as independent determinant of vitamin D status either per se or in combination with any other risk factor, even though lean to markedly centrally obese (ICO > 0.6) subjects were included. Life-style associated factors not tracked in our study, such as physical activity particularly if performed outdoors, dietary intake of vitamin D, or genetic variations, and duration of obesity could play a role.

25(OH)D₃ and non-standard cardiometabolic risk factors. Several lines of evidence point to strong associations between oxidative stress, microinflammation, and cardiovascular risk. Inflammation and oxidative stress act as cooperative and synergistic partners in the pathogenesis of hypertension (reviewed in [21]). Obesity is closely linked to oxidative stress and low-grade systemic inflammation with subsequent dysregulation of adipokines and inflammatory cytokine production [51]. Insulin resistance may be at least partially mediated by mechanism involving oxidative stress (implying particularly angiotensin II) [52], and low grade inflammation [53]. Both, inflammatory mechanisms and enhanced lipid oxidation may lead from dyslipidemia to atherogenesis [54, 55]. The inflammatory response, production of reactive oxygen species and adipokines, among others, are affected by vitamin D [1, 8, 9, 11, 12].

Inflammatory and oxidative markers. Elevated levels of CRP, IL-6, TNF-α or AOPPs (markers of phagocyte-mediated oxidative stress and inflammatory syndrome) predict future cardiovascular events or increased risk of T2DM in apparently healthy subjects or non-diabetic patients with decreased renal function [56–59]. In different populations (i.e. hypertensives, obese subjects, elderly), 25(OH)D₃ levels associate inversely with multiple inflammatory markers (i.e. hsCRP, hsTNF-α, AOPPs, pro-inflammatory cytokines), suggesting a potential anti-inflammatory role for vitamin D [20, 60–62]. In our study increasing number of cardiometabolic risk factors was associated with higher hsCRP, while levels of IL-6, hsTNF-α and AOPP/Alb were similar. IL-6 and hsTNF-α showed no significant association with 25(OH)D₃ levels, while those of hsCRP and AOPP/Alb could not be reliably approximated due to non-linear distribution of these markers even after their log transformation. Thus, the clinical impact of anti-inflammatory action of vitamin D in general population remains uncertain.

Advanced glycation end products and sRAGE. AGEs, formed by non-enzymatic glycation of proteins and under enhanced oxidative and carbonyl stress, exert inflammatory, pro-oxidant, and atherogenic effects via interaction with specific cell-surface receptor–RAGE [63]. Circulating sRAGE may act as a decoy [63]. Rise in circulating AGE and decline in sRAGE levels accompany hypertension, obesity, cardiovascular, and renal diseases; while both AGEs and sRAGE are elevated in diabetes [64–67].
In our study presence of ≥ 3 cardiometabolic risk factors was associated with the highest AGE-Fl/Alb, while with the lowest CML/Alb levels. AGE-Fl/Alb represent a bulk estimate of circulating AGE products with intrinsic fluorescence, while CML is a non-fluorescent and the most abundant circulating AGE compound, acting as a RAGE ligand [27]. Obesity-, elevated blood pressure-, insulin resistance- or atherogenic lipid profile-associated enhanced oxidative stress might trigger AGE formation. The apparently contradictory finding of lower CML/Alb in subjects presenting cardiometabolic risk factors probably reflects trapping of lipophilic CML into fat tissue, resulting in low levels of circulating CML in obese subjects [68, 69]. We did not reveal significant association between AGE/Alb or CML/Alb levels and the 25(OH)D₃. However, in streptozotocin-induced diabetic rats increased deposition of CML in aortic wall was blunted by administration of cholecalciferol, affecting probably the oxidative-stress mediated pathways [70]. To the best of our knowledge no human data on the effect of vitamin D supplementation on circulating or tissue AGEs are currently available.

sRAGE levels were decreased in subjects presenting ≤3 cardiometabolic risk factors, but no significant association between sRAGE and the 25(OH)D₃ status was revealed. Experimental and clinical data suggest that vitamin D might affect RAGE. In cell culture studies calcitriol blunted the AGEs- or lipopolysaccharide-induced up-regulation of RAGE mRNA and protein and counteracted their stimulating effect on NF-κB pathway [71, 72]. In streptozotocin-induced diabetic rats calcitriol treatment attenuated the increased expressions of cardiac RAGE, probably via modulating effect on angiotensin II receptor 1 [73]. Administration of calcitriol to 25(OH)D₃ deficient women with polycystic ovary syndrome was associated with rise in circulating sRAGE and an increase in sRAGE positively correlated with that of serum 25(OH)D₃ [74]. The mechanisms are unclear, but active vitamin D enhances the expression of matrix metalloproteinase-9 (MMP-9) shedding the cell-surface located RAGE [75, 76]. Thus, elucidation of potential functional relationship between the 25(OH)D₃ status and RAGE or sRAGE in apparent health requires further studies.

**Adipokines.** Large population studies indicate a direct relationship between serum 25(OH)D₃ and adiponectin [77, 78]. A smaller study reported a negative correlation with leptin, no relationship to adiponectin and resistin in healthy population, and no significant relationship in morbidly obese subjects [79]. In our study adipokine levels were significantly altered in the presence of cardiometabolic risk factors, but no association with the 25(OH)D₃ status was revealed. Reasons for discordance in clinical data remain unclear.

**Limitations**

The strength of our study is the large number of investigated non-diabetic medication-free adults not supplemented with 25(OH)D₃, recruited from restricted geographical area of Western Slovakia; and a wide scale of investigated non-standard cardiometabolic risk factors. However, the study encounters several limitations. 25(OH)D₃ status determination and the classification of presence of cardiometabolic risk factors was based on a single examination. We recruited approximately 50% less subjects presenting 3-to-4 cardiometabolic risk factors in comparison with other 2 groups, mirroring the fact that generally such subjects are on medication. Our subjects were not completely independent—family and household members participated. Nutritional intake of vitamin D was not ascertained. Being cross-sectional in its nature, our study allows commenting only on associations—pathomechanisms involved, causality or the direction of potential causal associations cannot be determined. Additional limitations are discussed above in relation to pertinent subject.
Conclusion

In non-diabetic medication-free adults specific combination of manifested cardiometabolic risk factors rather than their number associates with lower 25(OH)D3 levels. Elucidation of hypovitaminosis D association with particular combinations of classical cardiometabolic risk factors might be of clinical importance in identification of the subjects who are most likely to benefit from vitamin D supplementation. The modulatory impact of 25(OH)D3 on classical as well as non-standard cardiometabolic risk factors (e.i. inflammatory and oxidative stress markers, adipokines and AGE/RAGE axis) definitely requires further studies, as it might be disparate in apparent health and under disease-imposed burden.

Author Contributions

Conceived and designed the experiments: ZK MG KŠ. Performed the experiments: ZK MG. Analyzed the data: KŠ. Wrote the paper: KŠ ZK MG.

References

1. Mutt SJ, Hyppönen E, Saarnio J, Järvelin MR, Herzig KH. Vitamin D and adipose tissue—more than storage. Front Physiol. 2014; 5:228 doi: 10.3389/fphys.2014.00228 PMID: 25009502
2. Wong MSK, Delansorne R, Man RYK, Svenningsen P, Vanhoutte PM. Chronic treatment with vitamin D lowers arterial blood pressure and reduces endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2010; 299(4):H1226–H34. doi: 10.1152/ajpheart.00288.2010 PMID: 20693391
3. Li YC, Kong J, Wei MJ, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D-3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229–38. doi: 10.1172/jci200215219 PMID: 12122115
4. Li YC. Vitamin D Receptor Signaling in Renal and Cardiovascular Protection. Semin Nephrol. 2013; 33(5):43–47. doi: 10.1016/j.semnephrol.2013.07.005 PMID: 24119849
5. Bland R, Markovic D, Hills CE, Hughes SV, Chan SLF, Squires PE, et al. Expression of 25-hydroxyvitamin D-3-1 alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004; 89(1–5):121–5. doi: 10.1016/j.jsbmb.2004.03.115 PMID: 15225758
6. Maestro B, Davila N, Carranza MC, Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol. 2003; 84(2–3):223–30. doi: 10.1016/s0960-0760(03)00032-3 PMID: 12711007
7. Sooy K, Schermerhorn T, Noda M, Surana M, Rhoten WB, Meyer M, et al. Calbindin-D-28k controls Ca2+ (i) and insulin release—Evidence obtained from calbindin-D-28k knockout mice and beta cell lines. J Biol Chem. 1999; 274(48):34343–9. doi: 10.1074/jbc.274.48.34343 PMID: 10567411
8. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandi D, Friedl J, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006; 36(2):361–70. doi: 10.1002/eji.200425995 PMID: 16402404
9. Baker RG, Hayden MS, Ghosh S. NF-kappa B, Inflammation, and Metabolic Disease. Cell Metab. 2011; 13(1):11–22. doi: 10.1016/j.cmet.2010.12.008 PMID: 21195345
10. Sung CC, Liao MT, Lu KC, Wu CC. Role of Vitamin D in Insulin Resistance. J Biomed Biotechnol. 2012; Article Number: 634195. doi: 10.1155/2012/634195
11. Manucha W, Ritchie B, Ferder L. Hypertension and insulin resistance: implications of mitochondrial dysfunction. Curr Hypertens Rep. 2015; 17(1):504. doi: 10.1007/s11906-014-0504-2 PMID: 25432896
12. Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr. 2012; 108(11):1915–23. doi: 10.1017/s0007114512003285 PMID: 23048765
13. Zemel MB, Shi H, Greer B, DiRienzo D, Zemel PC. Regulation of adiposity by dietary calcium. FASEB J. 2000; 14(9):1132–8. PMID: 10894935
14. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009; 89(5):1321–7. doi: 10.3945/ajcn.2008.27004 PMID: 19321573
15. Cho HJ, Kang HC, Choi SA, JuYC, Lee HS, Park HJ. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biol Pharm Bull. 2005; 28(8):1418–23. doi: 10.1248/bpb.28.1418 PMID: 16079486
16. Kamycheva E, Jorde R, Figenschau Y, Haug E. Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest. 2007; 30(2):126–32. PMID: 17392602

17. Boucher BJ. Vitamin D Insufficiency and Diabetes Risks. Curr Drug Targets. 2011; 12(1):61–87. PMID: 20795936

18. Wolden-Kirk H, Gysemans C, Verstuyf A, Mathieu C. Extraskeletal Effects of Vitamin D. Endocrinol Metab Clin North Am. 2012; 41(3):571–94. doi: 10.1016/j.ecl.2012.05.004 PMID: 22877430

19. Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, et al. Vitamin D: beyond the bone. Ann N Y Acad Sci. 2013; 1287:45–58. doi: 10.1111/nyas.12129 PMID: 23682710

20. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations? Am J Med. 2010; 123(4):335–41. doi: 10.1016/j.amjmed.2009.09.024 PMID: 20362753

21. Crowley SD. The Cooperative Roles of Inflammation and Oxidative Stress in the Pathogenesis of Hypertension. Antioxid Redox Signal. 2014; 20(1):102–20. doi: 10.1089/ars.2013.5258 PMID: 23472597

22. Riachy R, Vandewalle B, Conte JK, Moerman E, Zacchetti P, Lukowiak B, et al. 1,25-dihydroxyvitamin D-3 protects RINm5F and human islet cells against cytokine-induced apoptosis: Implication of the anti-apoptotic protein A20. Endocrinology. 2002; 143(12):4809–19. doi: 10.1210/en.2002-220449 PMID: 12446608

23. Riachy R, Vandewalle B, Moerman E, Belaich S, Lukowiak B, Gmyr V, et al. 1,25-dihydroxyvitamin D-3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the fas receptor. Apoptosis. 2006; 11(2):151–9. doi: 10.1007/s10495-006-3558-z PMID: 16502254

24. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009; 20(11):1807–20. doi: 10.1007/s00198-009-0954-6 PMID: 19543765

25. Vitko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 2002; 168(5):2524–32. PMID: 9725252

26. Anderstam B, Ann-Christin BH, Valli A, Stenvinkel P, Lindholm B, Sulin MAE. Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta. 2008; 393(2):114–8. doi: 10.1016/j.cca.2008.03.029 PMID: 18423381

27. Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 1997; 35(9):669–77. PMID: 9352229

28. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85(7):2410–20. PMID: 10902785

29. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an athrogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001; 34(7):583–9. doi: 10.1016/s0009-9120(01)00263-6 PMID: 11738396

30. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1–87. PMID: 11090278

31. McCarthy HD, Ashwell M. A study of central fatness using waist-to-height ratios in UK children and adolescents over two decades supports the simple message ‘keep your waist circumference to less than half your height’. International Journal of Obesity. 2006; 30(6):988–92. doi: 10.1038/sj.ijo.0803226 PMID: 16432546

32. Pludowski P, Grant WB, Bhatta HP, Bayer M, Povoroznyuk V, Rudenko E, et al. Vitamin D Status in Central Europe. Int J Endocrinol. 2014; 2014:589587. doi: 10.1155/2014/589587 PMID: 24790600

33. Gonzalez-Gross M, Valtuena J, Breidenassel C, Moreno LA, Ferrari M, Kersting M, et al. Vitamin D status among adolescents in Europe: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. Br J Nutr. 2012; 107(5):755–64. doi: 10.1017/s0007114511003527 PMID: 21846429

34. Stürmer M, Šebeková K, Fazeli G, Bahner U, Stäb F, Heidland A. 25-Hydroxyvitamin D and Advanced Glycation End Products in Healthy and Hypertensive Subjects: Are There Interactions? J Renal Nutr. 2015; 25(2):209–16. doi: 10.1053/j.jrn.2014.10.027

35. Vojtková J, Ciljaková M, Vojarová L, Janíková K, Michnová Z, Sagiová V. Hypovitaminosis D in children with type 1 diabetes mellitus and its influence on biochemical and densitometric parameters. Acta Medica (Hradec Kralove). 2012; 55(1):18–22.
36. Štefková K, Spustová V, Krivošíková Z, Oká A, Gazdíková K, Fedelešová V, et al. Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2–3. Physiol Res. 2011; 60 (1):149–55. PMID: 20949598

37. Brazdilova K, Dlesk A, Koller T, Kullinger Z, Payer J. Vitamin D deficiency—a possible link between osteoporosis and metabolic syndrome. Bratisl Lek Listy. 2012; 113(7):412–6. doi: 10.4149/BLL_2012_093 PMID: 22794515

38. Štefková K, Krivošíková Z, Spustová V, Chylová K, Dzúrik R. Kidney function and age related mineral imbalance in postmenopausal women with osteopenia/osteoporosis. Bratisl Lek Listy. 2003; 104 (10):305–8. PMID: 15055729

39. Tamez H, Kalim S, Thadhani RI. Does vitamin D modulate blood pressure? Curr Opin Nephrol Hypertens. 2013; 22(2):204–9. doi: 10.1097/MNH.0b013e32835d919b PMID: 23299053

40. Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol. 2013; 28(3):205–21. doi: 10.1007/s10654-013-9790-2 PMID: 23456138

41. El-Fakhri N, McDevitt H, Shaikh MG, Halsey C, Ahmed SF. Vitamin D and Its Effects on Glucose Homeostasis, Cardiovascular Function and Immune Function. Horm Res Paediatr. 2014; 81(6):363–78. doi: 10.1159/000357731 PMID: 24776698

42. Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013; 72(1):89–97. doi: 10.1017/s0029665112002765 PMID: 23107484

43. Abbasi F, Feldman D, Caufield MP, Hantash FM, Reaven GM. Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension. Am J Hypertens. 2015; 28(2):266–72. doi: 10.1093/ajh/hpu136 PMID: 2531875

44. Wang L, Song YQ, Manson JE, Pilz S, Marz W, Michaelsson K, et al. Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease A Meta-Analysis of Prospective Studies. Circ Cardiovasc Qual Outcomes. 2012; 5(6):819–29. doi: 10.1161/circoutcomes.112.967604 PMID: 23194428

45. Schottker B, Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011; 50(4):303–10. doi: 10.1016/j.plipres.2011.05.001 PMID: 21640757

46. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011; 50(4):303–10. doi: 10.1016/j.plipres.2011.05.001 PMID: 2164075

47. Garcia-Bailo B, Da Costa LA, Arora P, Karmali M, El-Sohemy A, Badawi A. Plasma Vitamin D and Biomarkers of Cardiometabolic Disease Risk in Adult Canadians, 2007–2009. Prev Chronic Dis. 2013; 10:120230. doi: 10.5888/pcd10.120230

48. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts. Plos Med. 2013; 10(2):e1001383. doi:10.1371/journal.pmed.1001383 PMID: 23393431

49. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012; 71(2):332–8. doi:10.1017/s0029665112000092 PMID: 22429824

50. Henrikson EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011; 51(5):993–1019. doi:10.1016/j.freeradbiomed.2011.05.008 PMID: 21683347

51. Yudkin JS. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res. 2007; 39(10):707–9. doi: 10.1055/s-2007-985898 PMID: 17952830

52. Rizzo M, Kotur-Stevuljevic J, Berneis K, Spustová V, Chylová K, Dzúrik R. Kidney function and age related mineral imbalance in postmenopausal women with osteopenia/osteoporosis. Bratisl Lek Listy. 2003; 104 (10):305–8. PMID: 15055729

53. El-Fakhri N, McDevitt H, Shaikh MG, Halsey C, Ahmed SF. Vitamin D and Its Effects on Glucose Homeostasis, Cardiovascular Function and Immune Function. Horm Res Paediatr. 2014; 81(6):363–78. doi: 10.1159/000357731 PMID: 24776698

54. Homeostasis, Cardiovascular Function and Immune Function. Horm Res Paediatr. 2014; 81(6):363–78. doi: 10.1159/000357731 PMID: 24776698

55. Tuomisto K, Joussilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality—A population-based, prospective study. Thromb Haemost. 2006; 95(3):511–8. doi: 10.1160/th05-08-0571 PMID: 16525580
57. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20):1557–65. doi: 10.1056/NEJMoa021993 PMID: 12432042

58. Wang X, Bao W, Liu J, OuYang YY, Wang D, Rong S, et al. Inflammatory Markers and Risk of Type 2 Diabetes A systematic review and meta-analysis. Diabetes Care. 2013; 36(1):166–75. doi: 10.2337/dc12-0702 PMID: 23264288

59. Descamps-Latscha A, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005; 45(1):39–47. doi: 10.1053/ajkd.2004.09.011 PMID: 15696442

60. Kuloglu O, Gur M, Seker T, Kalkan GY, Sahin DY, Tanboga IH, et al. Serum 25-Hydroxyvitamin D Level Is Associated With Arterial Stiffness, Left Ventricular Hypertrophy, and Inflammation in Newly Diagnosed Hypertension. J Investig Med. 2013; 61(6):989–94. doi: 10.231/j/im.0b013e31829a82bc PMID: 2379941

61. De Vita F, Lauretani F, Bauer J, Bautmans I, Shardell M, Cherubini A, et al. Relationship between vitamin D and inflammatory markers in older individuals. Age (Dordr) 2014; 36(4):9694. doi: 10.1007/s11357-014-9694-4

62. Gradinaru D, Borsa C, Ionescu C, Margina D, Prada GI, Jansen E. Vitamin D status and oxidative stress markers in the elderly with impaired fasting glucose and type 2 diabetes mellitus. Aging Clin Exp Res. 2012; 24(6):595–602. doi: 10.3275/8591 PMID: 22968324

63. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005; 83(11):876–86. doi: 10.1007/s00109-005-0687-7

64. Mallipattu SK, Uribarri J. Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease? Curr Opin Nephrol Hypertens. 2014; 23(6):547–54. doi: 10.1097/MNH.0000000000000062 PMID: 25160075

65. Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE System in Cardiovascular Disease. Curr Pharm Design. 2014; 20(14):2395–402. doi: 10.2174/13816128113199990475

66. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis. 2009; 19(12):1177–86. doi: 10.1016/j.numecd.2008.03.004 PMID: 18595673

67. Vlassara H, Striker GE. Advanced Glycation Endproducts in Diabetes and Diabetic Complications. J Endocrinol Metab Clin North Am. 2013; 42(4):697–719. doi: 10.1016/el.2013.07.005 PMID: 24286947

68. Sebekova K, Somoza V, Jarusukova M, Heidland A, Podracka L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes. 2009; 4(2):112–8. doi: 10.1080/17477160802248939 PMID: 18645732

69. Sembra RD, Arab L, Sun K, Nicklett DJ, Ferrucci L. Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr. 2011; 141(9):1726–30. doi: 10.3945/jn.111.143172 PMID: 21775524

70. Salum E, Kals J, Kampus P, Salum T, Zilmer M, Aunapuu M, et al. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. Diabet Res Clin Pract. 2013; 100(2):243–9. doi: 10.1016/j.diabres.2013.03.008 PMID: 23522919

71. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008; 294(5):F1059–F64. doi: 10.1152/ajprenal.00051.2008 PMID: 18353875

72. Talmor Y, Bernheim J, Klein O, Green J, Raishid G. Calcitriol blunts pro-atherosclerotic parameters through NF kappa B and p38 in vitro. Eur J Clin Invest. 2008; 38(8):548–54. doi: 10.1111/j.1365-2362.2008.01977.x PMID: 18171824

73. Lee TW, Kao YH, Lee TI, Chang CJ, Lien GS, Chen YJ. Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts. Int J Cardiol. 2014; 173(2):236–41. doi: 10.1016/j.ijcard.2014.02.041 PMID: 24630581

74. Imani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab. 2014; 99(5):E886–90. doi: 10.1210/jc.2013-4374 PMID: 24606102

75. Lin R, Amizuka N, Sasaki T, Aarts MM, Ozawa H, Goltzman D, et al. 1-alpha,25-dihydroxyvitamin D-3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 8. J Bone Miner Res. 2002; 17(9):1604–12. doi: 10.1359/jbmr.2002.17.9.1604 PMID: 12211430
76. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008; 283(51):35507–16. doi:10.1074/jbc.M806948200 PMID: 18952609

77. Husemoen LLN, Skaaby T, Martinussen T, Jorgensen T, Thuesen BH, Kistorp C, et al. Investigating the causal effect of vitamin D on serum adiponectin using a mendelian randomization approach. Eur J Clin Nutr. 2014; 68(2):189–95. doi:10.1038/ejcn.2013.233 PMID: 24219894

78. Vaidya A, Williams JS, Forman JP. The Independent Association Between 25-Hydroxyvitamin D and Adiponectin and Its Relation With BMI in Two Large Cohorts: The NHS and the HPFS. Obesity. 2012; 20(1):186–91. doi:10.1038/oby.2011.210 PMID: 21760630

79. Vilarrasa N, Vendrell J, Maravall J, Elio I, Solano E, Jose PS, et al. Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population? Endocrine. 2010; 38(2):235–42. doi:10.1007/s12020-010-9379-4 PMID: 21046484